Valuation: Alligator Bioscience AB

Market Cap 14.45M 1.46M 1.28M 1.21M 1.1M 2.05M 141M 2.06M 5.57M 71.46M 5.5M 5.38M 230M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 14.45M 1.46M 1.28M 1.21M 1.1M 2.05M 141M 2.06M 5.57M 71.46M 5.5M 5.38M 230M EV / Sales 2026 *
2.45x
EV / Sales 2027 * 0.29x
Free-Float
83.58%
Yield 2026 *
-
Yield 2027 * -
1 day-99.99%
1 week+1,313.66%
Current month+855.06%
1 month+872.42%
3 months+89.21%
6 months+64.40%
Current year-0.28%
1 week 0.02
Extreme 0.0221
0.32
1 month 0.02
Extreme 0.0221
0.32
Current year 0.02
Extreme 0.0221
0.42
1 year 0.02
Extreme 0.0221
5.42
3 years 0.02
Extreme 0.0221
1,508
5 years 0.02
Extreme 0.0221
3,509.77
10 years 0.02
Extreme 0.0221
34,002.21
Manager TitleAgeSince
Chief Executive Officer 55 31/05/2021
Director of Finance/CFO 61 11/08/2024
Chief Tech/Sci/R&D Officer - 31/03/2025
Director TitleAgeSince
Chairman 55 -
Director/Board Member 64 31/05/2021
Director/Board Member 68 08/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-99.99%+1,313.66% - - 1.46M
+0.11%+2.71%+0.33%+28.59% 46.28B
-1.12%+1.78%+40.07%+27.26% 43.85B
-3.04%-6.29%+322.27%+517.36% 40.93B
-0.74%+1.25%+2.32%+67.94% 39.9B
-0.50%+0.67%+11.79%+40.51% 29.5B
-0.46%+4.22%+21.99%+124.21% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.15%+38.93% 15.22B
-3.14%+31.91%-10.60% - 14.05B
Average -10.89%+3.76%+51.29%+120.69% 29.15B
Weighted average by Cap. -1.02%+1.87%+64.69%+130.23%

Financials

2026 *2027 *
Net sales 5.9M 598K 522K 493K 447K 838K 57.4M 842K 2.28M 29.18M 2.25M 2.2M 93.9M 49.7M 5.04M 4.39M 4.15M 3.77M 7.06M 484M 7.09M 19.18M 246M 18.93M 18.51M 791M
Net income -15.2M -1.54M -1.34M -1.27M -1.15M -2.16M -148M -2.17M -5.87M -75.18M -5.79M -5.66M -242M 28.9M 2.93M 2.56M 2.41M 2.19M 4.1M 281M 4.12M 11.15M 143M 11.01M 10.76M 460M
Net Debt - -
Logo Alligator Bioscience AB
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Employees
11
Date Price Change Volume
18/09/26 SEK 0.0229 -2.35% 1,164,034
16/09/26 SEK 0.0234 +4.46% 100,000
14/09/26 SEK 0.0224 -1.32% 4,000
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!